The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema
Open accessAbstract
PURPOSE: To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex, DEX implant) 0.7 and 0.35 mg in the treatment of patients with diabetic macular edema (DME). DESIGN: Two randomized, multicenter, masked, sham-controlled, phase III clinical trials with identical protocols were conducted. Data were pooled for analysis. PARTICIPANTS: Patients (n = 1048) with DME, best-corrected visual acuity (BCVA) of 20/50 to 20/200 Snellen equivalent, and central retinal thickness (CRT) of ≥300 μm by optical coherence tomography. METHODS: Patients were randomized in a 1:1:1 ratio to study treatment with DEX implant 0.7 mg, DEX implant 0.35 mg, or sham procedure and followed for 3 years (or 39 months for patients treated at month 36) at ≤40 scheduled visits. Patients who met retreatment eligibility criteria could be retreated no more often than every 6 months. MAIN OUTCOME MEASURES: The predefined primary efficacy endpoint for the United States Food and Drug Administration was achievement of ≥15-letter improvement in BCVA from baseline at study end. Safety measures included adverse events and intraocular pressure (IOP). RESULTS: Mean number of treatments received over 3 years was 4.1, 4.4, and 3.3 with DEX implant 0.7 mg, DEX implant 0.35 mg, and sham, respectively. The percentage of patients with ≥15-letter improvement in BCVA from baseline at study end was greater with DEX implant 0.7 mg (22.2%) and DEX implant 0.35 mg (18.4%) than sham (12.0%; P ≤ 0.018). Mean average reduction in CRT from baseline was greater with DEX implant 0.7 mg (-111.6 μm) and DEX implant 0.35 mg (-107.9 μm) than sham (-41.9 μm; P < 0.001). Rates of cataract-related adverse events in phakic eyes were 67.9%, 64.1%, and 20.4% in the DEX implant 0.7 mg, DEX implant 0.35 mg, and sham groups, respectively. Increases in IOP were usually controlled with medication or no therapy; only 2 patients (0.6%) in the DEX implant 0.7 mg group and 1 (0.3%) in the DEX implant 0.35 mg group required trabeculectomy. CONCLUSIONS: The DEX implant 0.7 mg and 0.35 mg met the primary efficacy endpoint for improvement in BCVA. The safety profile was acceptable and consistent with previous reports.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Self-citationMitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Self-citationThe Prevalence of Diabetic Retinopathy Among Adults in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.552 · Cited by 1,148
Haller, J. A., Bandello, F., Belfort, R., Blumenkranz, M. S., Gillies, M., Heier, J., Loewenstein, A., Yoon, Y.-H., Jacques, M.-L., Jiao, J., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.03.032 · Cited by 1,068
Self-citationBrown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Self-citationMiyamoto, K., Khosrof, S., Bursell, S.-E., Rohan, R., Murata, T., Clermont, A. C., Aiello, L. P., Ogura, Y., & Adamis, A. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10836 · Cited by 788
Photocoagulation for Diabetic Macular Edema
Aiello, L. M., & Ferris, F. L. (1987) · Archives of Ophthalmology · doi:10.1001/archopht.1987.01060090021004 · Cited by 733
Cited by
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057
Diabetic Retinopathy Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.025 · Cited by 717
Mechanisms of macular edema: Beyond the surface
Daruich, A., Matet, A., Moulin, A., Kowalczuk, L., Nicolas, M., Sellam, A., Rothschild, P.-R., Omri, S., Gélizé, E., Jonet, L., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.006 · Cited by 708
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Self-citationDiabetic retinopathy - ocular complications of diabetes mellitus
Nentwich, M. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.489 · Cited by 553
Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets
Das, A., McGuire, P. G., & Rangasamy, S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.03.024 · Cited by 545
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
Tan, G. S., Cheung, N., Simó, R., Cheung, G. C. M., & Wong, T. Y. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30052-3 · Cited by 361
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., & Qiu, Q. (2022) · Cells · doi:10.3390/cells11213362 · Cited by 300
Kiziltoprak, H., Tekin, K., Inanc, M., & Goker, Y. S. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i3.140 · Cited by 282
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Li, S., Chen, L., & Fu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01992-2 · Cited by 277
Zur, D., Iglicki, M., Busch, C., Invernizzi, A., Mariussi, M., Loewenstein, A., Busch, C., Cebeci, Z., Chhablani, J. K., Chaikitmongkol, V., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.031 · Cited by 271
Sivaprasad, S., & Oyetunde, S. (2016) · Clinical Ophthalmology · doi:10.2147/opth.s100168 · Cited by 134
Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s383101 · Cited by 111
Self-citationComplications of intravitreal injections: 2022
Patel, D., Patel, S. N., Chaudhary, V., & Garg, S. J. (2022) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000850 · Cited by 92
Use of rabbit eyes in pharmacokinetic studies of intraocular drugs
Ahn, S. J., Hong, H. K., Na, Y. M., Park, S. J., Ahn, J., Oh, J., Chung, J. Y., Park, K. H., & Woo, S. J. (2016) · Journal of Visualized Experiments · doi:10.3791/53878 · Cited by 60
Economic Aspects in the Management of Diabetic Macular Edema in Italy
Calabrò, G. E., Basile, M., Varano, M., Amore, F., Ricciardi, R., Bandello, F., & Cicchetti, A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.938987 · Cited by 4
Self-citation
Metadata
- Authors
- Boyer, D. S., Yoon, Y. H., Belfort, R., Bandello, F., Maturi, R. K., Augustin, A. J., Li, X.-Y., Cui, H., Hashad, Y., & Whitcup, S. M.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 121
- Issue
- 10
- Pages
- 1904-1914
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W1972102480
- Cited by
- 1,122
- References
- 29
- FWCI
- 88.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.